Phesi publishes first edition of Digital Patient Profile Catalog to enable adoption of Digital Twins and improve patient centricity in drug development

Phesi publishes first edition of Digital Patient Profile Catalog to enable adoption of Digital Twins and improve patient centricity in drug development

Digital patient profiles based on data from more than 60 million patients generate a statistical view of patient attributes including demographics, diversity, comorbidities, concomitant medications and outcomes

BOSTON, USA, 03 MAY 2023: Phesi, a global provider of patient-centric data software and services, has today published the first edition of its Digital Patient Profile (DPP) catalog to deliver granular patient-level data for 28 key disease indications. The profiles, based on 485,000 curated clinical trials and amendments, and data from more than 60 million patients, provide a statistical view of patient attributes for 11 oncology indications and other prevalent diseases including Alzheimer’s, COVID-19, Crohn’s disease and ulcerative colitis. The profiles will be used by sponsors to improve program and trial protocol design, and enable the industry to develop Digital Twins and Digital Trial Arms as part of clinical development strategies. DPPs will also support wider adoption of single arm trials by helping sponsors demonstrate efficacy and safety in relevant patient cohorts. 

“Regulators, payers and patient advocacy groups are all pushing for program and protocol design to be more “patient-centric” and truly reflective of patient populations where there is unmet medical need. Doing so will significantly accelerate enrollment cycle times and reduce operational costs. But designing patient-centered programs is impossible without an accurate view of the patient population,” said Dr Gen Li, Founder and President, Phesi. “What we know about the global patient population has evolved significantly as medicine has advanced, along with other socioeconomic changes. Sponsors must use the data gathered from historical and existing trials and clinical research to move from “perception led” to “data led” program and study design. Launching this catalog of DPPs today is a first significant milestone for us and the industry. Using the Phesi analytics platform, we can create detailed profiles for over 4,000 disease indications and simulate clinical trials - accelerating the discovery of new medicines, reducing costs and reducing patient burden.”

The Phesi Trial Accelerator – which contains data from 90,000 dynamically updated sources, including 4.2m physicians and 60 million patients – was used to develop the DPP catalog. Each profile provides a statistical view of patient attributes for a given disease, and provides a granular breakdown of the patient population, including attributes such as age, sex, ethnicity and comorbidities, among many other key variables. DPPs can be leveraged to minimize overall operational costs, including from protocol amendments and non-active, non-enrolling sites, as well as enhancing submission packages for new drug approvals. DPPs are also used to predict trial outcomes via scenario modeling, including predicting risk factors, such as likely side effects resulting from the trial treatment.

“With a growing number of single-arm studies and trials with a small number of participants, it is critical to have the right cohort involved. Clinical trial designs that are not informed by data run the risk of developing drugs that are not efficacious for the target patient population,” commented Dr Li. “DPPs help sponsors understand how disease and patient profiles have evolved. For example, the typical breast cancer patient is getting younger, so studies now include more women of childbearing age. Such factors must be taken into account when developing new therapies, but an accurate view of the patient population is needed to do so. DPPs further enable sponsors to contextualize patient characteristics so they can more accurately interpret results from all small and/or single arm trials. Moreover, the insights from a DPP can be used to optimize large and costly Phase 3 trials from being conducted when they are not feasible nor commercially viable.”

The full DPP catalog can be accessed https://info.phesi.com/dpp. Phesi will be available to discuss the catalog during ASCO on booth #19169. The current edition of the catalog contains DPPs for the top five most studied disease areas as identified by a global analysis of 80,917 trial records. Three of the top five areas are in oncology, as follows: breast cancer, COVID-19, prostate cancer, solid tumors, and stroke.

Find out more about Phesi and Phesi Trial Accelerator™ platform.

About Phesi

Phesi is a global provider of AI-powered patient-centric data analytics, and clinical development products and solutions to the biopharmaceutical industry. The company’s integrated offerings cover the entire clinical development process — from development planning and indication assessment to protocol evaluation, site selection, and trial implementation management. Phesi has the world's largest and most dynamic real-time clinical development database; delivering patient-centric data science that enables biopharmaceutical companies to predict and optimize clinical development outcomes in any indication. Its database integrates data from 90,000 sources; consisting of records from 60+ million patients, 485,000+ curated clinical trials, 604,000 completed research projects, 4.2 million physicians, 600,000 investigator sites in 195 countries, and 4,000+ disease indications. Phesi delivers data, insights and answers, enabling smarter trials and faster cures. Visit www.phesi.com for more information.